Physician

Neil Howard Feldman, DO

According to 2025 Medicare claims, Neil Feldman, DO (NPI: 1699742486) practices allergy/immunology in the Allentown-Bethlehem-Easton, PA-NJ market, with the plurality of this provider's patient population coming from Lehigh, PA. This provider's primary affiliated billing organization is ALLERGY & ASTHMA ASSOCIATES P. C. (NPI: 1154389922; TIN: 23-1914238) and primary practice location at 18103-6217.

Feldman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 483 traditional Medicare patients, billed 48,338 HCPCS/CPT codes, and received $1,263,514 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,985 prescription claims across 388 beneficiaries totaling $397,991 in drug costs, led by Fasenra (Benralizumab). DME data shows 311 claims. Open Payments data shows 34 records totaling $799. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $335,528 to $1,263,514. Similarly, Part D prescription costs have risen steadily, from $257,794 to $397,991. In contrast, DME billing represents a smaller volume and moved from a higher plateau to a lower plateau, from $9,268 to $4,395.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	530	19,406	$335,528
2016	574	21,690	$389,269
2017	579	20,583	$446,560
2018	542	22,674	$602,668
2019	527	22,236	$702,011
2020	480	8,926	$195,149
2021	484	13,535	$253,803
2022	474	27,354	$768,036
2023	491	43,532	$1,188,336
2024	483	48,338	$1,263,514

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	260	1,475	$257,794
2016	301	1,593	$238,130
2017	316	1,574	$192,062
2018	362	1,881	$320,838
2019	367	1,935	$286,119
2020	358	1,693	$249,657
2021	349	1,737	$308,704
2022	371	1,881	$333,377
2023	353	1,780	$334,357
2024	388	1,985	$397,991

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	159	768	$36,049
2016	165	718	$30,698
2017	127	571	$21,985
2018	129	622	$15,576
2019	156	718	$19,092
2020	93	423	$16,413
2021	53	307	$15,435
2022	52	353	$23,812
2023	69	334	$20,986
2024	75	311	$18,317

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	282	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	409	875	$61
94010	Test to measure expiratory airflow and volume	81	87	$18
95165	Professional service for preparation and provision of 1 or more antigens	208	3,371	$9
95117	Professional service for multiple injections of allergen	222	2,303	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fasenra	Benralizumab	12	672	$69,073
Breo Ellipta	Fluticasone/Vilanterol	121	4,590	$57,789
Dupixent Pen	Dupilumab	12	336	$42,141
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	44	1,320	$26,286
Symbicort	Budesonide/Formoterol Fumarate	70	3,120	$24,375

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	12	$9,150
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	22	$3,248
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	36	97	$2,458
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	32	$1,997
Q0514	Pharmacy dispensing fee for inhalation drug(s); per 90 days	N	N/R	13	$673

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$799	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Neil Howard Feldman, DO?

Tedicare shows public-source Medicare data for Neil Howard Feldman, DO (NPI 1699742486), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Neil Howard Feldman, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Neil Howard Feldman, DO?

Neil Howard Feldman, DO is linked to ALLERGY & ASTHMA ASSOCIATES P. C. (billing NPI 1154389922) in the available physician profile data.

Does Neil Howard Feldman, DO have Open Payments data?

Neil Howard Feldman, DO has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.